1881. Costs of Treating Multidrug Resistant Tuberculosis in California, 2022

BACKGROUND: New, shorter regimens containing bedaquiline, pretomanid, and linezolid (BPaL) are entering clinical use for treating multidrug-resistant tuberculosis (MDR TB). Using a micro-costing approach, we estimated the direct cost of individual episodes of care for MDR TB for four different regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Katrak, Shereen, Wang, Rebecca, Barry, Pennan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677361/
http://dx.doi.org/10.1093/ofid/ofad500.1709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677361/
http://dx.doi.org/10.1093/ofid/ofad500.1709

Ejemplares similares